Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA): Look out for Analyst's Recommendation

Earnings Preview: What To Expect From Teva Pharmaceutical On Monday

Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted earnings of $1.31/Share in the previous quarter, as compared to earnings of $1.28/share estimated by analysts.

Revenues in the fourth quarter of 2016 were $6.49 billion, up 33% compared to the fourth quarter of 2015, primarily due to the inclusion, following the closing on August 2, of the results of the Actavis Generics business. The company's revenue for the quarter was up 33.0% on a year-over-year basis. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post $5.11 earnings per share for the current year.

Teva Pharmaceutical Industries Ltd (ADR) Last issued its quarterly earnings results on Nov 15, 2016. The firm has a market cap of $32.67 billion, a P/E ratio of 18.73 and a beta of 0.58. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -4.25% where SMA50 and SMA200 are -8.83% and -29.12% respectively.

TEVA was trading -44.55% below its 52-week high and 0.91% above its 52-week low. Stockholders of record on Thursday, March 2nd will be issued a $0.34 dividend. Boston Private Wealth LLC's holdings in Teva Pharmaceutical Industries Limited were worth $312,000 as of its most recent SEC filing. The stock is prone to big moves after reporting earnings and can easily gap up if the numbers are strong.

Investors have said Teva, which faces pricing pressure in its core generics business and recently lost protection on four of its patents for its key branded drug Copaxone for multiple sclerosis, must choose a new CEO with extensive pharmaceutical experience.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) now has a consensus Price Target of $42.09. Barclays PLC restated an "equal weight" rating and set a $46.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, November 30th.

Melania Trump Plans To Keep Michelle Obama's Famous Vegetable Garden
Melania Trump said the public tours will resume March 7 of the 224-year-old White House. The visits include self-guided tours from 7:30 11:30 a.m.

Shares of Teva were last seen up 2.3% at $34.80 on Tuesday, with a consensus analyst price target of $42.09 and a 52-week trading range of $31.90 to $59.35.

Deutsche Bank has a Buy rating and cut its price target to $45 from $48. Teva Pharmaceutical Industries Limited makes up 2.4% of Loudon Investment Management LLC's portfolio, making the stock its 11th largest position.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)'s stock had its "outperform" rating reissued by stock analysts at RBC Capital Markets in a research report issued to clients and investors on Tuesday. Its last 5-Year EPS growth stands at -13.10%; with earnings growth of 194.70% yoy. Sharkey Howes & Javer boosted its position in shares of Teva Pharmaceutical Industries Limited by 21.7% in the second quarter. The mean price target is $34.38 (according to consensus of 17 analysts).

We maintain our Neutral rating on TEVA shares. Washington Trust Bank increased its position in Teva Pharmaceutical Industries Limited by 2.7% in the third quarter. The company reported net sales of $764.3 million that increased 5.8% from the year-ago quarter and surpassed the Zacks Consensus Estimate of $724 million. While some analysts have a High Price target for the stock of $80 and a Low Price Target of $27. If you are reading this news story on another website, it was copied illegally and reposted in violation of global copyright and trademark laws. The correct version of this article can be accessed at [[permalink]]. "While we continue to manage through a turbulent and constantly evolving industry, we are committed to execute against our strategy with more diversified revenue sources and profit streams, all backed by strong product development engines in both generics and specialty".

Among analysts and investors, a widespread belief is that Teva could split in two-one side, the company's generics business, the other, its branded drug company. It has a global portfolio of approximately 1,000 molecules.

Related news: